N0539 phase ii trial of fulvestrant and bevacizumab in patients with metastatic breast cancer previously treated with an aromatase inhibitor: A north central cancer treatment group (now alliance) trial

Annals of Oncology

Volumn 24, Issue 10, 2013, Pages 2548-2554

  Tan, W W ^a   Dueck, A C ^a   Flynn, P ^b   Steen, P ^c   Anderson, D ^b   Rowland, K ^d   Northfelt, D ^a   Perez, E A ^a  

^a MAYO CLINIC   (United States)

^b Metro Minnesota CCOP   (United States)

^c Sanford Health South University   (United States)

^d Carle Cancer Center   (United States)

Author keywords

Antiangiogenesis agent; Aromatase inhibitor resistance; Bevacizumab; Estrogen receptor antagonist; Fulvestrant; Metastatic breast cancer

Indexed keywords

AROMATASE INHIBITOR; BEVACIZUMAB; FULVESTRANT;

ALLERGY; ARTICLE; BRAIN EMBOLISM; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; BREAST CANCER; CANCER SURVIVAL; CATHETER INFECTION; CLINICAL EFFECTIVENESS; CONFUSION; CONTROLLED STUDY; DIGESTIVE SYSTEM FISTULA; DIGESTIVE SYSTEM PERFORATION; DISEASE ASSOCIATION; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEADACHE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; INJECTION SITE REACTION; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; LOADING DRUG DOSE; LUNG HEMORRHAGE; METASTASIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; OCCLUSIVE CEREBROVASCULAR DISEASE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; QUALITY OF LIFE; SIDE EFFECT; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; VOMITING;

ANTIANGIOGENESIS AGENT; AROMATASE INHIBITOR RESISTANCE; BEVACIZUMAB; ESTROGEN RECEPTOR ANTAGONIST; FULVESTRANT; METASTATIC BREAST CANCER;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AROMATASE INHIBITORS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; ESTRADIOL; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; QUALITY OF LIFE; RECEPTORS, ESTROGEN; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84884721714     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt213     Document Type: Article

References (25)

1. Osborne CK, Coronado-Heinsohn EB, Hilsenbeck SG et al Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J Natl Cancer Inst 1995; 87: 746-750.
2. Howell A, Pippen J, Elledge RM et al Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials. Cancer 2005; 104: 236-239.
3. Liang Y, Brekken RA, Hyder SM. Vascular endothelial growth factor induces proliferation of breast cancer cells and inhibits the anti-proliferative activity of antihormones. Endocr Relat Cancer 2006; 13: 905-919.
4. Di Leo A, Jerusalem G, Petruzelka L et al Final analysis of overall survival for the Phase III CONFIRM trial: fulvestrant 500 mg versus 250 mg. Cancer Res 2012; 72: S1-S4.
5. Bretscher M, Rummans T, Sloan J et al Quality of life in hospice patients. A pilot study. Psychosomatics 1999; 40: 309-313.
6. Grunberg SM, Groshen S, Steingass S et al Comparison of conditional quality of life terminology and visual analogue scale measurements. Qual Life Res 1996; 5: 65-72.
7. Gudex C, Dolan P, Kind P et al Health state valuations from the general public using the visual analogue scale. Qual Life Res 1996; 5: 521-531.
8. Kansra S, Yamagata S, Sneade L et al Differential effects of estrogen receptor antagonists on pituitary lactotroph proliferation and prolactin release. Mol Cell Endocrinol 2005; 239: 27-36.
9. Obermiller AM, Copur MS. The longstanding quest for a better endocrine therapy continues high-dose fulvestrant: have we found its effective dose, combination, setting, or sequence? Contemporary Oncol 2011; 3: 1-5.
10. Croxtall JD, McKeage K. Fulvestrant: a review of its use in the management of hormone receptor-positive metastatic breast cancer in postmenopausal women. Drugs 2011; 71: 363-380.
11. Valachis A, Mauri D, Polyzos NP et al Fulvestrant in the treatment of advanced breast cancer: a systematic review and meta-analysis of randomized controlled trials. Crit Rev Oncol Hematol 2010; 73: 220-227.
12. Flemming J, Madarnas Y, Franek JA. Fulvestrant for systemic therapy of locally advanced or metastatic breast cancer in postmenopausal women: a systematic review. Breast Cancer Res Treat 2009; 115: 255-268.
13. Osborne CK, Pippen J, Jones SE et al Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol 2002; 20: 3386-3395.
14. Howell A, Robertson JF, Quaresma Albano J et al Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 2002; 20: 3396-3403.
15. Di Leo A, Jerusalem G, Petruzelka L et al Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol 2010; 28: 4594-4600.
16. Bergh J, Jonsson PE, Lidbrink EK et al FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer. J Clin Oncol 2012; 30: 1919-1925.
17. Mehta RS, Barlow WE, Albain KS et al A phase III randomized trial of anastrozole versus anastrozole and fulvestrant as first-line therapy for postmenopausal women with metastatic breast cancer: SWOG S0226. Cancer Res 2011; 71: S1-1.
18. Miles DW, Chan A, Dirix LY et al Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010; 28: 3239-3247.
19. Miller K, Wang M, Gralow J et al Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357: 2666-2676.
20. Robert NJ, Dieras V, Glaspy J et al RIBBON-1: randomized, double-blind, placebocontrolled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 2011; 29: 1252-1260.
21. Ingle JN, Suman VJ, Rowland KM et al Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group Trial N0032. J Clin Oncol 2006; 24: 1052-1056.
22. Chia S, Gradishar W, Mauriac L et al Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol 2008; 26: 1664-1670.
23. Yardley DA, Burris HA, 3rd, Clark BL et al Hormonal therapy plus bevacizumab in postmenopausal patients who have hormone receptor-positive metastatic breast cancer: a phase II Trial of the Sarah Cannon Oncology Research Consortium. Clin Breast Cancer 2011; 11: 146-152.
24. Martin M, Loibl S, von Minckwitz G et al Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer-first efficacy results from the LEA study. Cancer Res 2012; 72: 91s.
25. Baselga J, Campone M, Piccart M et al Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012; 366: 520-529.